Amyloid accumulation is a late event in sporadic Alzheimer's disease-like pathology in nontransgenic rats

Oncotarget

Volumn 6, Issue 3, 2015, Pages 1396-1413

  Stefanova, Natalia A ^a   Muraleva, Natalia A ^a   Korbolina, Elena E ^a   Kiseleva, Elena ^a   Maksimova, Kseniya Yi ^c   Kolosova, Nataliya G ^a,b,d  

^a INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

^b Institute of Mitoengineering   (Russian Federation)

^c SIBERIAN STATE MEDICAL UNIVERSITY   (Russian Federation)

^d NOVOSIBIRSK STATE UNIVERSITY   (Russian Federation)

Author keywords

Alzheimer's disease; Amyloid ; Mitochondria; Neurodegeneration; OXYS rats; Synaptic losses; Tau

Indexed keywords

AMYLOID; AMYLOID PRECURSOR PROTEIN; APOE4 PROTEIN; BETA SECRETASE 1; PICALM PROTEIN; PRESENILIN 1; PRESENILIN 2; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CASP3 GENE; CELL DEATH; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENETIC VARIABILITY; HISTOPATHOLOGY; MALE; NERVE CELL; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PROTEIN AGGREGATION; RAT; SENESCENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SORL1 GENE; WESTERN BLOTTING; AGE; ANIMAL; DISEASE MODEL; METABOLISM; MITOCHONDRION; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY; WISTAR RAT;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; MALE; MITOCHONDRIA; OXIDATIVE STRESS; RATS; RATS, WISTAR;

EID: 84922732740     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2751     Document Type: Article

References (58)

1. Morley JE, Armbrecht HJ, Farr SA, Kumar VB. The senescence accelerated mouse (SAMP8) as a model for oxidative stress and Alzheimer's disease. Biochim Biophys Acta. 2012; 1822:650-656.
2. Drachman DA. The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease. Alzheimers Dement. 2014; 3:372-380.
3. Morley JE, Farr SA. The role of amyloid-beta in the regulation of memory. Biochem Pharmacol. 2014; 88:479-485.
4. Krstic D, Knuesel I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol. 2013; 9:25-34.
5. Castellano JM, Deane R, Gottesdiener AJ, Verghese PB, Stewart FR, West T, Paoletti AC, Kasper TR, DeMattos RB, Zlokovic BV, Holtzman DM. Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proc Natl Acad Sci U S A. 2012; 109:15502-15507.
6. Kozhevnikova OS, Korbolina EE, Stefanova NA, Muraleva NA, Orlov YL, Kolosova NG. Association of AMD-like retinopathy development with an Alzheimer's disease metabolic pathway in OXYS rats. Biogerontology. 2013; 14:753-762.
7. Stefanova NA, Muraleva NA, Skulachev VP, Kolosova NG. Alzheimer's disease-like pathology in senescence-accelerated OXYS rats can be partially retarded with mitochondria-targeted antioxidant SkQ1. J Alzheimers Dis. 2014; 38:681-694.
8. Stefanova NA, Kozhevnikova OS, Vitovtov AO, Maksimova KY, Logvinov SV, Rudnitskaya EA, Korbolina EE, Muraleva NA, Kolosova NG. Senescenceaccelerated OXYS rats: a model of age-related cognitive decline with relevance to abnormalities in Alzheimer disease. Cell Cycle. 2014; 13:898-909.
9. Wolfe MS. When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease EMBO. 2007; Rep 8:136-140.
10. Stefanova NA, Fursova A, Kolosova NG. Behavioral effects induced by mitochondria-targeted antioxidant SkQ1 in Wistar and senescence-accelerated OXYS rats. J Alzheimers Dis. 2010; 21:479-491.
11. Stefanova NA, Fursova A, Sarsenbaev KN, Kolosova NG. Effects of Cistanche deserticola on behavior and signs of cataract and retinopathy in senescence-accelerated OXYS rats. J Ethnopharmacol. 2011; 138:624-632.
12. Youmans KL, Tai LM, Kanekiyo T, Stine WB Jr, Michon SC, Nwabuisi-Heath E, Manelli AM, Fu Y, Riordan S, Eimer WA, Binder L, Bu G, Yu C, Hartley DM, LaDu MJ. Intraneuronal Aβ detection in 5xFAD mice by a new Aβ-specific antibody. Mol Neurodegener. 2012; 7:8.
13. Mattson MP, Gleichmann M, Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron. 2008; 60:748-766.
14. de Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 2012; 73:685-697.
15. Piaceri I, Nacmias B, Sorbi S. Genetics of familial and sporadic Alzheimer's disease. Front Biosci (Elite Ed). 2013; 5:167-177.
16. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7:257-262.
17. Yagi R, Miyamoto R, Morino H, Izumi Y, Kuramochi M, Kurashige T, Maruyama H, Mizuno N, Kurihara H, Kawakami H. Detecting gene mutations in Japanese Alzheimer's patients by semiconductor sequencing. Neurobiol Aging. 2014; 7:1780.e1-e5.
18. Schmidt V, Carlo AS, Willnow TE. Apolipoprotein E receptor pathways in Alzheimer disease. Wiley Interdiscip Rev Syst Biol Med. 2014; 6:255-270.
19. Kamboh MI, Demirci FY, Wang X, Minster RL, Carrasquillo MM, Pankratz VS, Younkin SG, Saykin AJ, Jun G, Baldwin C, Logue MW, Buros J, Farrer L, et al. Genome-wide association study of Alzheimer's disease. Transl Psychiatry. 2012; 2:e117.
20. Shi H, Belbin O, Medway C, Brown K, Kalsheker N, Carrasquillo M, Proitsi P, Powell J, Lovestone S, Goate A, Younkin S, Passmore P. Genetic and Environmental Risk for Alzheimer's Disease Consortium, Morgan K; Alzheimer's Research UK Consortium. Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS). Neurobiol Aging. 2012; 33:1849.e5-e18.
21. Tan LI, Yu JT, Zhang W, Wu ZC, Zhang Q, Liu QY, Wang W, Wang HF, Ma XY, Cui WZ. Association of GWASlinked loci with late-onset Alzheimer's disease in a northern Han Chinese population. Alzheimers Dement. 2013; 9:546-553.
22. Wiwanitkit V. Physiological genomics analysis for Alzheimer's disease. Ann Indian Acad Neurol. 2013; 16:72-74.
23. Jarero-Basulto JJ, Luna-Muñoz J, Mena R, Kristofikova Z, Ripova D, Perry G, Binder LI, Garcia-Sierra F. Proteolytic cleavage of polymeric tau protein by caspase-3: implications for Alzheimer disease. J Neuropathol Exp Neurol. 2013; 72:1145-1161.
24. Yin RH, Yu JT, Tan L. The Role of SORL1 in Alzheimer's Disease. Mol Neurobiol. 2014; [Epub ahead of print] 24833601.
25. Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000; 283:1571-1577.
26. Struble RG, Ala T, Patrylo PR, Brewer GJ, Yan XX. Is brain amyloid production a cause or a result of dementia of the Alzheimer's type? J Alzheimers Dis. 2010; 22:393-399.
27. Parihar MS, Brewer GJ. Amyloid-beta as a Modulator of Synaptic Plasticity. J Alzheimers Dis. 2010; 22:741-763.
28. Stanga S, Lanni C, Govoni S, Uberti D, D'Orazi G, Racchi M. Unfolded p53 in the pathogenesis of Alzheimer's disease: is HIPK2 the link?. Aging. 2010; 2:545-554.
29. Kumar S, Walter J. Phosphorylation of amyloid beta (Aβ) peptides-a trigger for formation of toxic aggregates in Alzheimer's disease. Aging (Albany NY). 2011; 3:803-812.
30. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased Clearance of CNS beta-Amyloid in Alzheimer's Disease. Science. 2010; 330:1774.
31. Song B, Davis K, Liu XS, Lee HG, Smith M, Liu X. Inhibition of Polo-like kinase 1 reduces beta-amyloidinduced neuronal cell death in Alzheimer's disease. Aging (Albany NY). 2011; 3:846-851.
32. Brun A, Englund E. Regional pattern of degeneration in Alzheimer's disease: neuronal loss and histopathological grading. Histopathology. 1981; 5:549-564.
33. Wright AL, Zinn R, Hohensinn B, Konen LM, Beynon SB, Tan RP, Clark IA, Abdipranoto A, Vissel B. Neuroinflammation and Neuronal Loss Precede Ab Plaque Deposition in the hAPP-J20 Mouse Model of Alzheimer's Disease. PloS ONE. 2013; 8:e59586.
34. Jin KL, Peel AL, Mao XO, Xie L, Cottrell BA, Henshall DC, Greenberg DA. Increased hippocampal neurogenesis in Alzheimer's disease. Proc Natl Acad Sci U S A. 2004; 101:343-347.
35. Dumont M, Lin MT, Beal MF. Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease. J Alzheimers Dis. 2010; 20:S633-S643.
36. Jaszberenyi M, Rick FG, Szalontay L, Block NL, Zarandi M, Cai RZ, Schally AV. Beneficial effects of novel antagonists of GHRH in different models of Alzheimer's disease. Aging (Albany NY). 2012; 4:755-767.
37. Santos RX, Correia SC, Zhu X, Smith MA, Moreira PI, Castellani RJ, Nunomura A, Perry G. Mitochondrial DNA oxidative damage and repair in aging and Alzheimer's disease. Antioxid Redox Signal. 2013; 18:2444-2457.
38. Beregovoy NA, Sorokina NS, Starostina MV, Kolosova NG. Age-specific peculiarities of formation of long-term posttetanic potentiation in OXYS rats. Bull Exp Biol Med. 2011; 151:71-73.
39. Kolosova NG, Grishanova A, Krysanova ZS, Zueva TV, Sidorova IuA, Sinitsyna OI. Age-related changes in protein and lipid oxidation in the liver of prematurely aging rats OXYS. Biomed Khim. 2004; 50:73-78.
40. Kolosova NG, Shcheglova TV, Sergeeva SV, Loskutova LV. Long-term antioxidant supplementation attenuates oxidative stress markers and cognitive deficits in senescent-accelerated OXYS rats. Neurobiol Aging. 2006; 27:1289-1297.
41. Kozhevnikova OS, Korbolina EE, Ershov NI, Kolosova NG. Rat retinal transcriptome: effects of aging and AMD-like retinopathy. Cell Cycle. 2013; 12:1745-1761.
42. Maurer I, Zierz S, Moller HJ. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging. 2000; 21:455-462.
43. Shabalina IG, Kolosova NG, Grishanova A, Solov'ev VN, Salganik RI, Solov'eva NA. Oxidative phosphorylation activity, F0F1-ATPase and level of liver mitochondrial cytochromes in rats with congenitally increased ability for free radical formation. Biokhimiia. 1995; 60:2045-2052.
44. Kolosova NG, Aidagulova SV, Nepomnyashchikh GI, Shabalina IG, Shalbueva NI. Dynamics of structural and functional changes in hepatocyte mitochondria of senescence-accelerated OXYS rats. Bull Exp Biol Med. 2001; 132:814-819.
45. Vays VB, Eldarov CM, Vangely IM, Kolosova NG, Bakeeva LE, Skulachev VP. Antioxidant SkQ1 delays sarcopenia-associated damage of mitochondrial ultrastructure. Aging (Albany NY). 2014; 6:140-148.
46. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. 2007; San Diego, CA: Academic Press(Sixth Edition).
47. Alexopoulos P, Guo LH, Kratzer M, Westerteicher C, Kurz A, Perneczky R. Impact of SORL1 single nucleotide polymorphisms on Alzheimer's disease cerebrospinal fluid markers. Dement Geriatr Cogn Disord. 2011; 32:164-170.
48. Elias-Sonnenschein LS, Bertram L, Visser PJ. Relationship between genetic risk factors and markers for Alzheimer's disease pathology. Biomark Med. 2012; 6:477-495.
49. Willnow TE, Andersen OM. Sorting receptor SORLA-a trafficking path to avoid Alzheimer disease. J Cell Sci. 2013; 26:2751-2760.
50. Capsoni S, Carlo AS, Vignone D, Amato G, Criscuolo C, Willnow TE, Cattaneo A. SorLA deficiency dissects amyloid pathology from tau and cholinergic neurodegeneration in a mouse model of Alzheimer's disease. J Alzheimers Dis. 2013; 33:357-371.
51. Hansson CA, Frykman S, Farmery MR, Tjernberg LO, Nilsberth C, Pursglove SE, Ito A, Winblad B, Cowburn RF, Thyberg J, Ankarcrona M. Nicastrin, presenilin, APH-1, and PEN-2 form active gammasecretase complexes in mitochondria. J Biol Chem. 2004; 279:51654-51660.
52. Kandalepas PC, Vassar R. The Normal and Pathologic Roles of the Alzheimer's β-secretase, BACE1. Curr Alzheimer Res. 2014; 11:441-449.
53. Rhinn H, Fujita R, Qiang L, Cheng R, Lee JH, Abeliovich A. Integrative genomics identifies APOE e4 effectors in Alzheimer's disease. Nature. 2013; 500:45-50.
54. Rajagopalan P, Hibar DP, Thompson PM. TREM2 and neurodegenerative disease. N Engl J Med. 2013; 369:1565-1567.
55. Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell D, Bertelsen S, Bailey M, et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron. 2013; 78:256-268.
56. Cruchaga C, Karch CM, Jin SC, Benitez BA, Cai Y, Guerreiro R, Harari O, Norton J, Budde J, Bertelsen S, Jeng AT, Cooper B, Skorupa T, et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. Nature. 2014; 505:550-554.
57. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, et al. Association of apolipoprotein E allele epsilon 4 with lateonset familial and sporadic Alzheimer's disease. Neurology. 1993; 43:1467-1472.
58. Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, Bullido MJ, Engelborghs S, De Deyn P, Berr C, Pasquier F, Dubois B, Tognoni G, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry. 2011; 16:903-907.